@article {8531,
	title = {{The impact of APOE genotype on survival: Results of 38,537 participants from six population-based cohorts (E2-CHARGE)},
	journal = {PLoS One},
	volume = {14},
	year = {2019},
	pages = {e0219668},
	abstract = {Apolipoprotein E is a glycoprotein best known as a mediator and regulator of lipid transport and uptake. The APOE-{\^I}{\textmu}4 allele has long been associated with increased risks of Alzheimer{\textquoteright}s disease and mortality, but the effect of the less prevalent APOE-{\^I}{\textmu}2 allele on diseases in the elderly and survival remains elusive.\ We aggregated data of 38,537 individuals of European ancestry (mean age 65.5 years; 55.6\% women) from six population-based cohort studies (Rotterdam Study, AGES-Reykjavik Study, Cardiovascular Health Study, Health-ABC Study, and the family-based Framingham Heart Study and Long Life Family Study) to determine the association of APOE, and in particular APOE-{\^I}{\textmu}2, with survival in the population.\ During a mean follow-up of 11.7 years, 17,021 individuals died. Compared with homozygous APOE-{\^I}{\textmu}3 carriers, APOE-{\^I}{\textmu}2 carriers were at lower risk of death (hazard ratio,95\% confidence interval: 0.94,0.90-0.99; P = 1.1*10-2), whereas APOE-{\^I}{\textmu}4 carriers were at increased risk of death (HR 1.17,1.12-1.21; P = 2.8*10-16). APOE was associated with mortality risk in a dose-dependent manner, with risk estimates lowest for homozygous APOE-{\^I}{\textmu}2 (HR 0.89,0.74-1.08), and highest for homozygous APOE-{\^I}{\textmu}4 (HR 1.52,1.37-1.70). After censoring for dementia, effect estimates remained similar for APOE-{\^I}{\textmu}2 (HR 0.95,0.90-1.01), but attenuated for APOE-{\^I}{\textmu}4 (HR 1.07,1.01-1.12). Results were broadly similar across cohorts, and did not differ by age or sex. APOE genotype was associated with baseline lipid fractions (e.g. mean difference(95\%CI) in LDL(mg/dL) for {\^I}{\textmu}2 versus {\^I}{\textmu}33: -17.1(-18.1-16.0), and {\^I}{\textmu}4 versus {\^I}{\textmu}33: +5.7(4.8;6.5)), but the association between APOE and mortality was unaltered after adjustment for baseline LDL or cardiovascular disease. Given the European ancestry of the study population, results may not apply to other ethnicities.\ Compared with APOE-{\^I}{\textmu}3, APOE-{\^I}{\textmu}2 is associated with prolonged survival, whereas mortality risk is increased for APOE-{\^I}{\textmu}4 carriers. Further collaborative efforts are needed to unravel the role of APOE and in particular APOE-{\^I}{\textmu}2 in health and disease.},
	author = {Wolters, F. J. and Yang, Q. and Biggs, M. L. and Jakobsdottir, J. and Li, S. and Evans, D. S. and Bis, J. C. and Harris, T. B. and Vasan, R. S. and Zilhao, N. R. and Ghanbari, M. and Ikram, M. A. and Launer, L. and Psaty, B. M. and Tranah, G. J. and Kulminski, A. M. and Gudnason, V. and Seshadri, S.}
}
@article {9857,
	title = {{Cohort Profile: Dementia Risk Prediction Project (DRPP)},
	journal = {Int J Epidemiol},
	volume = {53},
	year = {2024},
	month = {Feb},
	author = {Krefman, A. E. and Stephen, J. and Carolan, P. and Sedaghat, S. and Mansolf, M. and Soumare, A. and Gross, A. L. and Aiello, A. E. and Singh-Manoux, A. and Ikram, M. A. and Helmer, C. and Tzourio, C. and Satizabal, C. and Levine, D. A. and Lloyd-Jones, D. and o, E. M. and Sorond, F. A. and Wolters, F. J. and Himali, J. and Launer, L. J. and Zhao, L. and Haan, M. and Lopez, O. L. and Debette, S. and Seshadri, S. and Judd, S. E. and Hughes, T. M. and Gudnason, V. and Scholtens, D. and Allen, N. B.}
}
